Trial Profile

An Open-Label, Single-Dose Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of MK-3543

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bomedemstat (Primary)
Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera; Small cell lung cancer
Focus Pharmacokinetics
Sponsors Merck Sharp & Dohme

Most Recent Events

03 Sep 2025 Planned End Date changed from 5 Dec 2025 to 16 Mar 2026.
03 Sep 2025 Status changed from not yet recruiting to recruiting.
11 Aug 2025 Planned initiation date changed from 7 Jul 2025 to 16 Aug 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com